-
Product Insights
NewSmoking Cessation – Drugs In Development, 2024
Empower your strategies with our Smoking Cessation – Drugs In Development, 2024 report and make more profitable business decisions. Smoking is addictive; smokers experience an uncontrollable dependence on cigarettes, and stopping can cause severe mental, emotional, or physical reactions. People addicted to smoking develop a tolerance to nicotine. Nicotine acts on acetylcholine receptors, causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological...
-
Product Insights
NewAlcohol Addiction – Drugs In Development, 2024
Empower your strategies with our Alcohol Dependence – Drugs In Development, 2024 report and make more profitable business decisions. Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking, and violent behavior. Risk factors include age, family history, and depression or other mental health problems. The Alcohol Dependence drugs in development market research report provide comprehensive information on the therapeutics under development for Alcohol Dependence, complete with...
-
Product Insights
NewOpium (Opioid) Addiction – Drugs In Development, 2024
Empower your strategies with our Opium (Opioid) Addiction – Drugs In Development, 2024 report and make more profitable business decisions. Opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers, known as endorphins). This can lead to an inability of the body to stop pain, because there are no endorphins to mask the pain initially. The degeneration...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NYPRG-101 in Cluster Headache Syndrome (Cluster Headache)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NYPRG-101 in Cluster Headache Syndrome (Cluster Headache) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NYPRG-101 in Cluster Headache Syndrome (Cluster Headache) Drug Details:NYPRG-101 (BOL-148)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Cluster Headache Syndrome (Cluster Headache)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Cluster Headache Syndrome (Cluster Headache) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Cluster Headache Syndrome (Cluster Headache) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BMS-986012 in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986012 in Small-Cell Lung Cancer Drug Details:BMS-986012 is under development for the treatment of solid tumor...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Norovirus [Strains Norwalk Gi.1 +...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPT-155 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPT-155 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPT-155 in Solid Tumor Drug Details: FPT-155 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-2846 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-2846 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-2846 in Prostate Cancer Drug Details: AL-2846 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cobimetinib Fumarate in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cobimetinib Fumarate in Refractory Multiple Myeloma Drug Details:Cobimetinib (GDC-0973 / RG7421...